Abstract:Yueyuan Wang, &ast Bo Lv, &ast Kai Fan, Cunjin Su, Delai Xu, Jie Pan Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jie Pan; Delai Xu, Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215004, People's Republic of China, Email ; Purpose: Parkinson's disease (PD) is a common neurodegenerative disease that severely affects patients' daily lives and places a significant burden on the global economy. There are currently no specific biomarkers for distinguishing between the different stages of PD. Methods: We divided 78 mice into six equal groups, including five model PD groups (W1–W5; based on the PD stage induced by length of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/propofol induction time) and a control group. Then, we used metabolomics technology to detect the serum small-molecule metabolites present in each group. Ultimately, we screened for potential biomarkers using the variable importance in the projection of the orthogonal partial least squares discriminant analysis and the coefficient value of LASSO ordinal logistic regression. Results: We identified 12 potential biomarkers, including dehydroepiandrosterone sulfate, pipecolic acid, N-acetylleucine, 2-aminoadipic acid, L-tyrosine, uric acid, and 5-hydroxyindoleacetaldehyde. Pathway analysis revealed their involvement in amino acid metabolism, caffeine metabolism, steroid hormone biosynthesis, and purine metabolism. Additionally, the receiver operating characteristic curve indicated that a biomarker panel comprising the 12 biomarkers could differentiate between the different PD stages. Conclusion: Different PD stages are characterized by different metabolites. The biomarkers identified in this study are helpful to understand the PD process. Keywords: Parkinson's disease, metabolomics, biomarkers, metabolic disturbances, LC–MS Parkinson's disease (PD), the second most common chronic neurodegenerative disease after Alzheimer's disease, is a multisystem disorder with multiple mechanisms and neurochemical features. It affects 2% of people aged >65 years and 4% of people aged >80 years. 1–3 The number of people with PD is expected to reach 12 million by 2050 4 , and this increased incidence may cause high economic and social burdens. PD is a multifactorial and sporadic disease. Its highly complex pathogenesis has not been fully elucidated and may be related to mitochondrial dysfunction, oxidative stress, and the inflammatory response. 5 The diagnostic criteria for PD include the recognition of specific clinical symptoms that are already evident in the patient, usually several years after the neurodegenerative process has occurred. Additionally, even if the diagnostic criteria are correctly applied, the rate of PD misdiagnosis is high for some nonspecific clinical symptoms. Although positron emission tomography and single-photon emission computed tomography imaging are highly sensitive and can be used for imaging diagnosis of PD, they are not specific to PD, are costly, and carry the risk of radiation exposure. Therefore, it is crucial to investigate the mechanisms and evolution of PD and to search for PD biomarkers. 6 Metabolomics is the science of quantitatively measuring the composition of all metabolites of a biological system (cell models, tissues, organs, or whole organisms), usually small-molecule metabolites with relative molecular masses <1000, as well as dynamic alterations in these metabolites in response to internal and external stimuli. 7 This rapidly developing emerging discipline follows the advent of genomics, transcriptomics, and proteomics and has been widely used in various fields, such as nutrition, toxicology, and disease diagnosis. 8 Improvements in high-resolution mass spectrometry technology have led to the increasingly extensive application of metabolomics technology in clinical medicine, especially in screening for disease biomarkers and intrinsic regulatory mechanisms. Metabolites play active regulatory roles in systems biology, and metabolomics tools provide a direct functional readout of an organism's physiological state, which is difficult to obtain using other histological methods. Thus, the resultant metabolic profile is a complete description of the organism's phenotype. 9 In recent years, the development of analytical and bioinformatic tools has resulted in the exponential growth of metabolomics research. Further studies, such as the functional analysis of metabolites, may lead to the discovery of relevant bioinformation, such as protei -Abstract Truncated-

Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Quantitative proteomic analysis of mitochondrial proteins: relevance to Lewy body formation and Parkinson's disease.

Metabolic Disturbances in a Mouse Model of MPTP/Probenecid-Induced Parkinson's Disease: Evaluation Using Liquid Chromatography-Mass Spectrometry

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson’s disease

Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis

Identification of gut metabolites associated with Parkinson's disease using bioinformatic analyses

Comprehensive blood metabolomics profiling of Parkinson’s disease reveals coordinated alterations in xanthine metabolism

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Predictive Modeling of Alzheimer’s and Parkinson’s Disease Using Metabolomic and Lipidomic Profiles from Cerebrospinal Fluid

Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease

Advances of Mechanisms-Related Metabolomics in Parkinson’s Disease

The role of dopaminergic medication, lipid, and endocannabinoid pathway alterations in idiopathic and -mediated Parkinson’s disease – a large-scale targeted metabolomics study

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Simple biomarkers to distinguish Parkinson's disease from its mimics in clinical practice: a comprehensive review and future directions

Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients

Lipid metabolic dysregulation is involved in Parkinson’s disease dementia

Metabolomics of Blood Reveals Age-Dependent Pathways in Parkinson’s Disease

Multi-Omics Integration in Mice With Parkinson’s Disease and the Intervention Effect of Cyanidin-3-O-Glucoside

Comprehensive proteomics of CSF, plasma, and urine identify DDC and other biomarkers of early Parkinson's disease

Metabolic network connectivity disturbances in Parkinson's disease: a novel imaging biomarker